Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vvDD-CCL5
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intraperitoneal
01
Overview
vvDD-CCL5 is an oncolytic vaccinia virus (VACV) engineered for enhanced tumor selectivity and immunogenicity. The "vvDD" backbone refers to a "double-deleted" vaccinia virus where the genes for thymidine kinase (TK) and vaccinia growth factor (VGF) have been removed to restrict viral replication to rapidly dividing malignant cells. This specific construct is further "armed" with a transgene encoding the chemokine CCL5 (also known as RANTES). CCL5 expression within the tumor microenvironment is intended to recruit immune effector cells, such as T cells and dendritic cells, thereby converting "cold" tumors into "hot" tumors and enhancing the anti-tumor immune response. Research has demonstrated its efficacy in murine models of colon cancer and malignant mesothelioma, particularly when combined with other immunotherapies like IL-2 or checkpoint inhibitors.
- Other names
- CCL5-expressing double-deleted vaccinia virusCCL-5-expressing double-deleted vaccinia virusCCL 5-expressing double-deleted vaccinia virusRANTES-expressing double-deleted vaccinia virusvvDD-mCCL5vvDD-mCCL-5vvDD-mCCL 5
02
Targets
HS/GAGs (Heparan sulfate and related glycosaminoglycans)CCR5 (C-C chemokine receptor type 5)CCR1CCR3 (C-C chemokine receptor type 3)
Beyond the preview
Go deeper on vvDD-CCL5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vvDD-CCL5.